Endo and Bioprojet sign agreement for commercialization of pitolisant in Canada
Endo's subsidiary Endo Ventures has entered into definitive agreements with Bioprojet SCR to register, commercialize, and distribute pitolisant on an exclusive basis in Canada. Paladin Labs, an operating company of Endo, will be commercializing pitolisant in Canada. Pitolisant is a selective histamine H3-receptor antagonist/inverse agonist that enhances the activity of histaminergic neurons. The drug is approved in the EU for the treatment of narcolepsy in adult patients with or without cataplexy, but is not approved in Canada. Pitolisant has an orphan designation in the EU and the US for the treatment of narcolepsy. Paladin will be responsible for the registration distribution, sales, marketing, medical affairs, pricing and reimbursement activities in connection with pitolisant while Bioprojet will be responsible for supplying the drug to Paladin.